Treating azotemia-induced anemia with erythropoietin improves diabetic eye disease

Kidney International, Supplement

Volumn 64, Issue 87, 2003, Pages

  Friedman, Eli A ^a   L'Esperance Jr , Francis A ^b   Brown, Clinton D ^b   Berman, David H ^b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b NONE

Author keywords

Diabetes; Erythropoietin; Hypoxia; Macular edema; Nephropathy; Pseudohypoxia; Retinopathy

Indexed keywords

CALCIUM CARBONATE; ERYTHROPOIETIN; FUROSEMIDE; INSULIN; LISINOPRIL; METOLAZONE; TOLAZAMIDE;

ADULT; ANEMIA; ARTICLE; BLOOD RHEOLOGY; CASE REPORT; DIABETES MELLITUS; DISEASE COURSE; EYE DISEASE; FEMALE; FLUORESCENCE ANGIOGRAPHY; HEMATOCRIT; HUMAN; KIDNEY FUNCTION; PRIORITY JOURNAL; UREMIA; VISUAL IMPAIRMENT; WELLBEING; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; INSULIN DEPENDENT DIABETES MELLITUS; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PAPILLEDEMA;

ANEMIA; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; ERYTHROPOIETIN; FEMALE; HUMANS; MIDDLE AGED; PAPILLEDEMA; UREMIA;

EID: 0142231522     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.64.s87.9.x     Document Type: Article

References (43)

1. CENTERS FOR DISEASE CONTROL AND PREVENTION: Diabetes: Disabling, deadly, and on the rise. National diabetes fact sheet: National estimates and general information on diabetes in the United States. Atlanta, GA, National Center for Chronic Disease Prevention and Health Promotion, 2002
2. HJELM K, MUFUNDA E, NAMBOZI G, KEMP J: Preparing nurses to face the pandemic of diabetes mellitus: A literature review. Adv Nurs 41:424-34, 2003
3. UNITED STATES RENAL DATA SYSTEM: Annual Data Report. Atlas of End-Stage Disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2002
4. RESNIKOFF S: The cost of diabetes. International Diabetes Foundation Web Site World Health Organization. http://www.idf.org/ home, press release 2003
5. MAUER SM, CHAVERS BM: A comparison of kidney disease in type I and type II diabetes. Adv Exp Med Biol 189:299-303, 1985
6. FRIEDMAN EA, L'ESPERANCE FA, JR (editors): Diabetic Renal-Retinal Syndrome. New York, Grune & Stratton, Inc., 1980
7. ARUN CS, NGUGI N, LOVELOCK L, et al: Effectiveness of screening in preventing blindness due to diabetic retinopathy. Diabet Med 20:186-190, 2003
8. BROWN CD, FRIEDMAN EA: Stable renal function and benign course in azotemic diabetics treated with erythropoietin for one year. Contrib Neph 88:182-191, 1991
9. BERMAN D, FRIEDMAN EA: Absorption of hard exudates after treatment with erythropoietin. Retina 14:1-5, 1994
10. WELLS RF, JR, DENTEN R, MERRILL EW: Measurement of viscosity of biologic fluids by cone plate viscometer. J Lab Clin Med 57:646-656, 1961
11. STUDY ETDR: Manual of Operations, chapter 18. Springfield, VA, United States Department of Commerce, National Technical Information Service, 1979
12. ESCHBACH JW, EGRIE JC, DOWNING MR, et al: Correction of the anemic of end-stage renal disease with recombinant human erythropoietin: Results of a phase I and II clinical trial. N Engl J Med 316:73-78, 1987
13. OFSTHUN N, LABRECQUE J, LACSON E, et al: The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney 63:1908-1914, 2003
14. KULZER P, SCHAEFER RM, KRAHN R, et al: Effectiveness and safety of recombinant human erythropoietin (r-HuEPO) in the treatment of anemia of chronic renal failure in non dialysis patients. Eur Multicentre Study Group. Int J Artif Organs 17:195-202, 1994
15. JUNGERS PY, ROBINO C, CHOUKROUN G, et al: Incidence of anaemia, and use of epoetin therapy in pre-dialysis patients: A prospective study in 403 patients. Nephrol Dial Transplant 17:1621-1627, 2002
16. KOENE RA, FRENKEN LA: Does treatment of predialysis patients with recombinant human erythropoietin compromise renal function? Contrib Nephrol 87:105-112, 1990
17. BRESNICK G: Background diabetic retinopathy. In: RYAN SJ, SCHACHAT AP, MURPHY RP, PATZ A, editors: Retina. St. Louis, CV Mosby, 1989, pp 327-366
18. BRESNICK GH: Diabetic maculopathy: A critical review highlighting diffuse macular edema. Ophthalmology 90:1301-1317, 1983
19. GREEN WR: Retina. In: SPECER WH, editor: Ophthalmic Pathology. Philadelphia, WB Saunders, 1985, pp 589-1291
20. PELZEK C, LIM JI: Diabetic macular edema: Review and update. Ophthalmol Clin North Am 15:555-563, 2002
21. BRESNICK GH: Diabetic maculopathy: a review. Ophathalmology 93:989-997, 1986
22. DUNCAN LJP, CULLEN JF, IRELAND JT, et al: A three year trial of atromid therapy in exudative diabetic retinopathy. Diabetes 17: 458-459, 1968
23. GORDON B, CHANG S, Kavangh M, et al: The effects of lipid lowering on diabetic retinopathy. Am J Ophthalmol 112:385-391, 1992
24. FUNATSU H, YAMASHITA H, NOMA H, et al: Outcome of vitreous surgery and the balance between vascular endothelial growth factor and endostatin. Invest Ophthalmol Vis Sci 44:1042-1047, 2003
25. FRANK RN: On the pathogenesis of diabetic retinopathy: A 1990 update. Ophthalmology 98:586-593, 1991
26. D'AMICO DJ: Diseases of the retina. N Engl J Med 331:95-106, 1994
27. INGBER D, FUJITA T, KISHIMOTO S, et al: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348:555-557, 1990
28. LE DEVCHAT C, KHODABANDEHLOU T: Transcutaneous oxygen pressure and hemorheology in diabetes mellitus. Int Angiol 9:259-262, 1990
29. SANTILLI SM, FIEGEL VD, KNIGHTON DR: Alloxan diabetes alters the rabbit transarterial wall oxygen gradient. J Vasc Surg 18:227-233, 1993
30. WILLIAMSON JR, CHANG K, FRANGOS MY: Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42:801-813, 1993
31. HAMPTON KK, ALANI SM, WILSON JI, et al: Resistance to ischaemic conduction failure in chronic hypoxaemia and diabetes. J Neurol Neurosurg Psychiatry 52:1303-1305, 1989
32. Low PA, SCHMELZER JD, WARD KK, et al: Effect of hyperbaric oxygenation on normal and chronic strptozotocin diabetic peripheral nerves. Exp Neurol 99:201-212, 1988
33. BROWNLEE M: Glycation and diabetic complications. Diabetes 43:836-841, 1994
34. WOLF AS, BOSCH RJ, FINE LG: TI growth factors in the pathogenesis of renovascular complications of diabetes mellitus. Hypertens 10(1):S11-6, 1992
35. CAMERON NE, COTTER MA, ROBERTSON S: Angiotensin converting enzyme inhibition prevents development of muscle and nerve dysfunction and stimulated angiogenesis in strptozotocin-diabetic rats. Diabetologia 35:12-18, 1992
36. EARLE K, VIBERTI GC: Familial, hemodynamic and metabolic factors in the predisposition to diabetic kidney disease. Kidney Int 452:434-7, 1994
37. BROWNLEE M: Biochemistry and molecular cell biology of diabetic complications. Nature 13:813-820, 2001
38. HERNANDEZ C, LECUBE A, SEGURA RM, et al: Nitric oxide and vascular endothelial growth factor concentrations are increased but not related in vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med 19:655-660, 2002
39. NOMA H, FUNATSU H, YAMASHITA H, et al: Regulation of angiogenesis in diabetic retinopathy: Possible balance between vascular endothelial growth factor and endostatin. Arch Ophthalmol 120: 1075-1080, 2002
40. DIKOW R, SCHWENGER V, SCHÖMIG M, et al: How should we manage anaemia in patients with diabetes? Nephrol Dial Transplant 17 (Suppl 1):67-72, 2002
41. NIKOLOV V, KALAYDJIEVA V, LOGOFETOV A: Plasma erythropoietin activity in diabetes patients, studied by determining the 59Fe incorporation in posthypoxic polycythemic mice. Acta Physiol Pharacol Bulg 15:37-40, 1989
42. NIELSEN OJ, MANDRUP-POULSEN T, NERUP J: Deficiency of erythropoietin is not responsible for the anaemia associated with cyclosporin treatment of insulin-dependent diabetes mellitus. Canadian-European Randomized Control Trial Group. J Intern Med 233:471-476, 1993
43. SINCLAIR SH, DELVECCHIO C, LEVIN A: Treatment of anemia in the diabetic patient with retinopathy and kidney disease. Am J Ophthalmol 135:740-743, 2003